AstraZeneca Sues To Block Lupin's Generic Seroquel XR

Law360, New York (November 9, 2012, 3:02 PM EST) -- AstraZeneca Pharmaceuticals LP has hit Lupin Ltd. with a patent infringement suit in New Jersey federal court, adding the India-based drugmaker to the long list of companies it has sued for trying to market generic versions of extended-release schizophrenia drug Seroquel XR.

The suit filed Nov. 5 alleges Lupin infringed AstraZeneca's U.S. Patent Number 5,948,437 by filing an abbreviated new drug application with the U.S. Food and Drug Administration that sought approval to make and sell generic versions of Seroquel XR.

AstraZeneca has asserted the '437...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.